CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
CA-008 5 mg +8 moredrug
Likely dose
CA-008 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03789318
NCT03789318Phase 2Completed

A Phase 2, Randomized, Double-blind, Placebo-Controlled Efficacy, Pharmacokinetics and Safety Study of CA-008 in Subjects Undergoing Complete Abdominoplasty

Concentric Analgesics·interventional·Posted Dec 28, 2018·Updated Mar 19, 2024

In Brief

A Phase 2 clinical trial evaluating CA-008 5 mg, Placebo, and 7 other interventions for Postsurgical Pain. Completed, enrolled 54 participants across 1 site.

Detailed Summary

Phase 2, single center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 vs. placebo in subjects undergoing an elective C-ABD under general anesthesia supplemented with a bupivacaine hydrochloride (HCl)transverse abdominis plane (TAP) block.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 28, 2018
Enrollment StartDec 3, 2018
Primary CompletionMay 16, 2019
Study CompletionJun 12, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.5 years ago

Interventions

CA-008 5 mgdrug

5 mg CA-008 reconstituted in saline.

Placebodrug

Each cohort will use placebo reconstituted in saline.

Bupivacaine Hydrochloridedrug

0.25% administered pre-surgery

Hydromorphonedrug

0.02 mg/kg IV administered intraoperatively

Fentanyldrug

100 mcg IV administered intraoperatively

Acetaminophendrug

1000 mg IV administered intraoperatively

Oxycodonedrug

5-10 mg PO administered post-surgery

CA-008 10 mgdrug

10 mg CA-008 reconstituted in saline.

CA-008 15 mgdrug

15 mg CA-008 reconstituted in saline.